Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sine-Off Claims To Fight Cough, Cold, Flu – And Meth Abuse

This article was originally published in The Tan Sheet

Executive Summary

Ads for reformulated Sine-Off cold and sinus products are scripted to position the brand as an active contributor to the nation's fight against methamphetamine abuse

You may also be interested in...



Replacing Pseudoephedrine Easier Said Than Done, OTC Firms Find

Reformulating pseudoephedrine products has posed a greater challenge than expected for a number of firms, as passage of a federal bill restricting sale of the ingredient looms

PSE-free products

Sine-Off is the "first and only brand" of cough, cold, flu and sinus medicine to "completely remove pseudoephedrine from all of its products - not only nasal decongestants," Hogil Pharmaceutical announces Dec. 7. The line, which is now reformulated with phenylephrine, includes Sinus & Cold, Multi-Symptomand Sinus Painand iscurrently available in major mass retailers and drugstores nationwide. In addition, Hogil and its Sine-Off Charitable Foundation will provide an unrestricted educational grant to the Partnership for a Drug-Free America to support anti-meth measures, the firm announces. The firm will donate a percentage of sales from Sine-Off products to local anti-drug charities as well...

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Topics

UsernamePublicRestriction

Register

PS099118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel